Logo image of CNVY

Convey Health Solutions Holdings Inc (CNVY) Stock Fundamental Analysis

USA - NYSE:CNVY - US21258C1080 - Common Stock

10.51 USD
-0.05 (-0.47%)
Last: 10/6/2022, 8:04:00 PM
10.51 USD
0 (0%)
After Hours: 10/6/2022, 8:04:00 PM
Fundamental Rating

2

Taking everything into account, CNVY scores 2 out of 10 in our fundamental rating. CNVY was compared to 35 industry peers in the Health Care Technology industry. CNVY may be in some trouble as it scores bad on both profitability and health. CNVY is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

CNVY had negative earnings in the past year.
CNVY Yearly Net Income VS EBIT VS OCF VS FCFCNVY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 0 10M -10M 20M 30M

1.2 Ratios

Industry RankSector Rank
ROA -0.76%
ROE N/A
ROIC 1.87%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CNVY Yearly ROA, ROE, ROICCNVY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 0 1 -1 2 -2

1.3 Margins

Industry RankSector Rank
OM 5.47%
PM (TTM) -1.9%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CNVY Yearly Profit, Operating, Gross MarginsCNVY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 0 10 20 30 40

More info and screens

2

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so CNVY is destroying value.
CNVY has more shares outstanding than it did 1 year ago.
Compared to 1 year ago, CNVY has an improved debt to assets ratio.
CNVY Yearly Shares OutstandingCNVY Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 20M 40M 60M
CNVY Yearly Total Debt VS Total AssetsCNVY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 200M 400M 600M 800M

2.2 Solvency

CNVY has an Altman-Z score of 1.68. This is a bad value and indicates that CNVY is not financially healthy and even has some risk of bankruptcy.
CNVY has a Debt/Equity ratio of 0.50. This is a healthy value indicating a solid balance between debt and equity.
Industry RankSector Rank
Debt/Equity 0.5
Debt/FCF N/A
Altman-Z 1.68
ROIC/WACC0.18
WACC10.35%
CNVY Yearly LT Debt VS Equity VS FCFCNVY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 0 100M 200M 300M 400M 500M

2.3 Liquidity

CNVY has a Current Ratio of 2.20. This indicates that CNVY is financially healthy and has no problem in meeting its short term obligations.
CNVY has a Quick Ratio of 1.60. This is a normal value and indicates that CNVY is financially healthy and should not expect problems in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 2.2
Quick Ratio 1.6
CNVY Yearly Current Assets VS Current LiabilitesCNVY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 20M 40M 60M 80M 100M

More info and screens

6

3. Growth

3.1 Past

CNVY shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 28.74%, which is quite impressive.
CNVY shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 16.45%.
The Revenue has been growing by 23.55% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)28.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
Revenue 1Y (TTM)16.45%
Revenue growth 3Y23.55%
Revenue growth 5YN/A
Sales Q2Q%19.31%

3.2 Future

CNVY is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 91.65% yearly.
The Revenue is expected to grow by 15.76% on average over the next years. This is quite good.
EPS Next Y406.25%
EPS Next 2Y171.28%
EPS Next 3Y119.84%
EPS Next 5Y91.65%
Revenue Next Year19.05%
Revenue Next 2Y17.57%
Revenue Next 3Y16.68%
Revenue Next 5Y15.76%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
CNVY Yearly Revenue VS EstimatesCNVY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 200M 400M 600M
CNVY Yearly EPS VS EstimatesCNVY Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 0 0.5 1 1.5

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CNVY. In the last year negative earnings were reported.
CNVY is valuated rather expensively with a Price/Forward Earnings ratio of 24.03.
When comparing the Price/Forward Earnings ratio of CNVY to the average of the S&P500 Index (22.87), we can say CNVY is valued inline with the index average.
Industry RankSector Rank
PE N/A
Fwd PE 24.03
CNVY Price Earnings VS Forward Price EarningsCNVY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 -50 -100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA 19.33
CNVY Per share dataCNVY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as CNVY's earnings are expected to grow with 119.84% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y171.28%
EPS Next 3Y119.84%

More info and screens

0

5. Dividend

5.1 Amount

CNVY does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Convey Health Solutions Holdings Inc

NYSE:CNVY (10/6/2022, 8:04:00 PM)

After market: 10.51 0 (0%)

10.51

-0.05 (-0.47%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)08-12 2022-08-12/amc
Earnings (Next)11-09 2022-11-09/amc
Inst Owners0.11%
Inst Owner Change0%
Ins Owners1.08%
Ins Owner Change0%
Market Cap769.56M
Analysts48.89
Price Target11.22 (6.76%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 24.03
P/S 2.1
P/FCF N/A
P/OCF N/A
P/B 1.45
P/tB N/A
EV/EBITDA 19.33
EPS(TTM)-0.1
EYN/A
EPS(NY)0.44
Fwd EY4.16%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS5
BVpS7.25
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -0.76%
ROE N/A
ROCE N/A
ROIC 1.87%
ROICexc N/A
ROICexgc 12.86%
OM 5.47%
PM (TTM) -1.9%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.4
Health
Industry RankSector Rank
Debt/Equity 0.5
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.2
Quick Ratio 1.6
Altman-Z 1.68
F-Score6
WACC10.35%
ROIC/WACC0.18
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)28.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
EPS Next Y406.25%
EPS Next 2Y171.28%
EPS Next 3Y119.84%
EPS Next 5Y91.65%
Revenue 1Y (TTM)16.45%
Revenue growth 3Y23.55%
Revenue growth 5YN/A
Sales Q2Q%19.31%
Revenue Next Year19.05%
Revenue Next 2Y17.57%
Revenue Next 3Y16.68%
Revenue Next 5Y15.76%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A